Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Amgen logo
AmgenAMGN
$0
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$42K
Arcus Biosciences logo
Arcus BiosciencesRCUS
$0
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.26B+91.5%
Enterprise value$3.34B+92.0%
P/S+0.6×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemAmortizedcostUnrealizedgainsUnrealizedlossesEstimatedfair value
Money market funds and cash$28,658$28,658
Certificates of deposit5,4635,463
Total cash and cash equivalents$34,121$34,121
Marketable securities:
Commercial paper$16,584$(17)$16,567
Corporate debt securities94,3251(192)94,134
U.S. Treasury and agency securities93,856(126)93,730
Total marketable securities$204,765$1$(335)$204,431

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s unrealized gains on investments?
Arcutis Biotherapeutics, Inc. (ARQT) reported unrealized gains on investments of $1K in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s unrealized gains on investments changed year-over-year?
Arcutis Biotherapeutics, Inc.'s unrealized gains on investments decreased by 98.9% year-over-year, from $90K to $1K.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s unrealized gains on investments?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s unrealized gains on investments has grown at a 80.5% compound annual growth rate (CAGR), from $7K to $134K.
What does unrealized gains on investments mean?
The total unrealized gains on investments, typically related to available-for-sale securities.

Ask your AI about Arcutis Biotherapeutics, Inc.'s unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude